Bruce Sands, MD: Phase 3 Treat-Through Data for Mirikizumab in Crohn’s Disease
Sands reviews key findings from the phase 3 VIVID-1 study of mirikizumab in Crohn’s disease presented at DDW.
Alan Bonder, MD: Phase 2 Data for Combination Obeticholic Acid, Bezafibrate in PBC
Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.
Anthony Lembo, MD: Exploring Probiotics for IBS Treatment
Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.
Brian Lacy, MD, PhD: Assessing, Treating Chronic Abdominal Bloating and Distension
Lacy reviews key considerations for the diagnostic evaluation and treatment of abdominal bloating and distension based on his session at DDW.
Elizabeth Aby, MD: Financial Burden in Adults Undergoing Liver Transplant Evaluation
Aby describes findings from a pair of studies presented at DDW exploring the prevalence and impact of financial burden in liver transplant candidates.
Prashant Singh, MD: Rethinking the Low FODMAP Diet for IBS-D
Singh explains a potential new approach to the low FODMAP diet based on findings from research he presented at DDW suggesting a simplified step-up method.
Intestinal Ultrasound’s Value for Assessing Disease Activity in IBD, with Noa Krugliak Cleveland, MD
Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.
Ali Rezaie, MD: Exploring a Palatable Approach to the Elemental Diet
Rezaie reviews findings from a prospective clinical trial of a novel palatable elemental diet, highlighting its 100% compliance rate and strong efficacy.
Remo Panaccione, MD: GALAXI 2, GALAXI 3 Data for Guselkumab in Crohn’s Disease
Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.
Francisca Joly, MD, PhD: Apraglutide in Short Bowel Syndrome with Intestinal Failure
Joly explains the burden of parenteral support and the significance of new STARS data showcasing apraglutide’s potential in SBS-IF.
Novel Endoscopy System Feasible for Evaluation of Upper GI Diseases
A cable-transmission magnetically controlled capsule endoscopy showed comparability to conventional methods in upper GI tract examinations and lesion detection.
Naim Alkhouri, MD: Interim Analysis of Phase 2 Survodutide Data Show Promise for MASH, Fibrosis
Alkhouri explains survodutide’s mechanism of action as a glucagon/GLP-1 receptor dual agonist and reviews key findings about its use in MASH from the interim analysis.
Blood-Based Test Offers Effective Screening Option for Colorectal Cancer
Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.
Clinical Quiz: AGA Recommendations on Endoscopic Eradication Therapy of Barrett’s Esophagus
A detailed overview and accompanying quiz on the recommendations made by the AGA in their 2024 guideline on endoscopic eradication
REGENERATE: Final Results for Obeticholic Acid for Pre-Cirrhotic Fibrosis Due to NASH
End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.
GALAXI 2 & 3: Guselkumab Superior to Ustekinumab for Crohn's Disease
Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.
STARS: Apraglutide Reduces Parenteral Support in Patients with Stoma, Colon-In-Continuity
New STARS data were presented in a late-breaking abstract at DDW and build upon positive topline results for clinical responder rates and reductions in parenteral support.
Paul Feuerstadt, MD: Safety, Efficacy of Live-jslm in Patients Taking Concomitant Medications
Feuerstadt breaks down findings from an ad hoc analysis of PUNCH CD3 and what the results suggest about the use of live-jslm (Rebyota) in patients taking concomitant medications.
Guselkumab Achieves Clinical, Endoscopic Remission in Ulcerative Colitis
The phase 3 QUASAR Maintenance study met its primary endpoint of clinical remission and demonstrated statistically significant endoscopic remission rates in UC treatment.
The Impact of GLP-1RA Use in Patients with IBD, with Priya Sehgal, MD, MPH
Sehgal explains the safety and efficacy of GLP-1RAs in patients with IBD as well as the impact on inflammatory biomarkers.
Oriana Damas, MD: Intervals of a Low-Calorie, Plant-Based Diet Show Promise for UC
Damas explains key findings from her pilot study exploring intervals of a low-calorie plant-based diet as adjunctive therapy to medication in patients with ulcerative colitis.
Ali Rezaie, MD: Trends in GLP-1RA Use Among Nondiabetic, Nonobese Patients
Rezaie describes recent trends in GLP-1RA prescription patterns from his population-based research presented at DDW, highlighting increases in off-label use.
Michael Dolinger, MD: Recognizing Intestinal Ultrasound’s Potential in Ulcerative Colitis
Dolinger reviews findings from his research presented at DDW about the use of intestinal ultrasound response for predicting endoscopic outcomes in children with UC.
Sweat-Based Wearable Device Monitors Key Markers of IBD Activity
TNF-α levels in the sweat correlate with serum values in patients with IBD, suggesting the wearable's feasibility in non-invasive disease monitoring.
Exploring Diet’s Role in Managing Ulcerative Colitis, with Oriana Damas, MD
Damas explains what inspired her research about the impact of a low-calorie plant-based diet on clinical response to medication in patients with ulcerative colitis.
Microbiota-Focused Dietary Modulation May Improve MAFLD Management
Microbiota differences between individuals with and without MAFLD were associated with dietary intake and clinical outcomes.
Breath Analysis Can Aid Clinical Characterization of Microbiome Metabolism
Findings were presented at DDW and highlight the feasibility of breath analysis for microbiome metabolic characterization in the digestive system.
Wei Zhang, MD, PhD: Recognizing Disparities in Hepatocellular Carcinoma Diagnosis, Care
Zhang explains disparities in HCC care and the negative impact on long-term outcomes, also addressing potential considerations for vulnerable patient populations.
Digital Health Monitoring Platforms Feasible for IBD Management
The MyGut digital health monitoring platform proves feasible and impactful during integration into inflammatory bowel disease care.
Study Assesses Predictive Markers of Resmetirom Histological Response in MAESTRO-NASH
Results presented at DDW detail the association between ALT, Fibroscan CAP, Fibroscan VCTE, and histological response to resmetirom in patients enrolled in MAESTRO-NASH.
